Fig. 6
From: Magnetic hyperthermia therapy enhances the chemoradiosensitivity of glioblastoma
MHT combined with CRT increases tumor response over single agent treatments in orthotopic SD3 human GBM tumors (5 × 105 cells/mouse). (A) Therapeutic scheme used for untreated controls (CT), fractionated CRT (5 mg/kg TMZ x2 + 5 Gy x2), MHT (MIONPs 80 mg/ml, 8ul + AMF 383.55 kHz, 8.28kA/m, 20 min) and MHT + CRT. (B) Representative MRI (T2WI) images showing infiltrative GBM xenografts 20-, 27- and 32-days post tumor cell implantation in the untreated control group (dotted circle). (C) H&E staining of intracranial GBM xenograft confirms tumor formation (magnification 100X) * = tumor core, star = normal brain tissue. (D) Prussian Blue staining of mouse brain section revealing intratumoral distribution of MIONPs 24 h post CED (magnification 40X). (E) Kaplan-Meier survival curve. P-value is calculated using the Gehan-Breslow Wilcoxon test.
